Loading...
•
Dec 31, 2023
Gossamer Bio Q4 2023 Earnings Report
Announced financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.
Key Takeaways
Gossamer Bio reported a net loss of $48.1 million for the quarter ended December 31, 2023, with cash, cash equivalents, and marketable securities totaling $296.4 million at year-end. The first PAH patient was dosed in the Phase 3 PROSERA study, and Japan was included in the study following CTN acceptance by PMDA.
First PAH patient dosed in the ongoing registrational Phase 3 PROSERA Study.
Inclusion of Japan in Phase 3 PROSERA Study following CTN acceptance by PMDA.
Cash, cash equivalents and marketable securities totaled $296.4 million at year-end 2023.
Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
Forward Guidance
Gossamer anticipates data readout from the Phase 3 PROSERA Study and is planning to commence a clinical development program in PH-ILD. The company may file a commercial marketing application in Japan pending clinical data and expects current resources to fund operations into the first half of 2026.
Positive Outlook
- Anticipated timing of a data readout from our Phase 3 PROSERA Study
- Expectations on commencing a clinical development program in PH-ILD
- The ability to file a commercial marketing application in Japan pending clinical data
- Expected timeframe for funding our operating plan with current cash, cash equivalents and marketable securities.
Challenges Ahead
- Potential delays in the commencement, enrollment and completion of clinical trials
- Disruption to our operations from pandemics, including clinical trial delays
- The Company’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...